Phase 4 N=132 Presbyopia-Correcting Intraocular Lenses (IOLs)
Cataract
Primary: Best Corrected Visual Acuity — -0.075; -0.080; -0.081; 0.227 logMAR
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=65 Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia
Presbyopia
Primary: Percentage of Participants With at Least a 2 Line Improvement From Baseline in Uncorrected Near Visual Acuity (UNVA) in the Non-Dominant Eye — 46.7; 70.6; 56.3; 68.8…
Phase 2 N=151 A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia
Presbyopia
Primary: Weighted Average Change From Baseline in Uncorrected Near Visual Acuity (UNVA) Letters in the Nondominant Eye — 3.00; 4.96; 7.77; 7.54 letters correctly read — p=0.1663
Phase 2 N=163 A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia
Presbyopia
Primary: Weighted Average Change From Baseline in Mesopic, High Contrast Uncorrected Near Visual Acuity (UNVA) Letters — 1.12; 3.83; 5.26; 5.42 letters correctly read — p=0.0029
Phase 3 N=323 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia
Presbyopia
Primary: Percentage of Participants Gaining 3 Lines or More in Mesopic, High-contrast, Binocular Distance-Corrected Near Visual Acuity (DCNVA) at Day 30, Hour 3 — 8.1; 30.7…
Phase 2 N=79 Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia
Presbyopia
Primary: Mean Change From Baseline in Binocular Distance Corrected Near Visual Acuity (DCNVA) — 4.1; 4.3; 4.4 EDTRS letters
Phase 3 N=230 A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily
Presbyopia
Primary: Percentage of Participants Gaining 3 Lines or More in Mesopic, High-Contrast, Binocular Distance-Corrected Near Visual Acuity (DCNVA) With No More Than 5-Letter Loss in…
Phase 2 N=58 A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia
Presbyopia
Primary: Proportion of Subjects With at Least a 3 Line (15 Letter) Improvement in Near Visual Acuity in the Study Eye — 47.22; 47.22; 2.38 percentage of participants — p=0.0009
Phase 2 N=75 A Study to Evaluate the Safety and Efficacy of EV06 Ophthalmic Solution in Improving Vision in Subjects With Presbyopia
Presbyopia
Primary: Ocular Comfort Assessment Following Instillation at Baseline and the Day Prior to Each Study Visit — 3.2; 3.3; 2.4; 2.2 units on a scale
Phase 3 N=469 Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia
Presbyopia · Refractive Error · Eye Diseases
Primary: Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance Vision — 48.68; 64.5; 11.49 percentage of participants — p=<0.0001
Phase 4 N=62 The Development of New Functions of Esculin and Digitalis Glycosides Eye Drops: A Study on the Treatment of Presbyopia
Presbyopia
Primary: DCNVA — 8; 1 Participants
N/A N=16 Trial of the PresVIEW Implant for the Improvement of Near Vision in Patients With Presbyopia
Presbyopia
Primary: Number of Primary Eyes With Distance Corrected Near Visual Acuity (DCNVA) to 20/40 or Better or Improvement of 2 or More Lines — 288 Primary Eyes — p=0.025
Phase 3 N=427 A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia
Presbyopia
Primary: Percentage of Participants Gaining 3 Lines or More in Mesopic, High-contrast, Binocular DCNVA, Without Losing More Than 5 Letters of Mesopic, High-Contrast, Binocular…
Phase 3 N=229 Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia
Presbyopia · Near Vision · Refractive Error
Primary: Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance Vision — 57.38; 70.59; 7.85 percentage of participants — p=<0.0001
N/A N=84 Accommodative Relief for Uncomfortable Non-Presbyopes
Asthenopia
Primary: Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) Score — 14.3; 12.8; 19.0 scores on a scale — p=<0.001
N/A N=121 OPTI-FREE® PureMoist® for Presbyopic Contact Lens Wearers
Presbyopia
Primary: Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) Score at Day 30 — 13.4; 15.8 units on a scale — p==0.0030
N/A N=31 A Clinical Trial of The VisAbility Micro Insert System for Presbyopic Patients
Presbyopia
Primary: Number of Primary Eyes With Distance Corrected Near Visual Acuity (DCNVA) to 20/40 or Better and Gain of At Least 10 Letters. — 289 Participants
Phase 2 N=68 Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
Presbyopia · Refractive Errors · Eye Diseases
Primary: Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance Vision — 56.0; 71.4; 5.9 percentage of participants — p=<0.0001
N/A N=16 Multifocal Contact Lens Use in Previous Contact Lens Wearers With Near Vision Demands
Presbyopia
Primary: Overall Satisfaction With the Lenses — 82.5; 64.4 Units on a Scale
N/A N=118 Safety and Effectiveness Study of the AcuFocus Corneal Inlay ACI 7000PDT in Presbyopes
Presbyopia
Primary: Improvement in Uncorrected Near Visual Acuity — 78.2 percentage of participants
Phase 2 N=59 Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia
Presbyopia · Refractive Errors · Eye Diseases
Primary: Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance Vision — 74.0; 75.5; 4.3 percentage of participants — p=<0.0001
Phase 3 N=182 Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia
Presbyopia
Primary: Proportion of Subjects With >=15 Letter Gain Without >=5 Letter Loss in Near Visual Acuity — 49.4; 35.0; 22.7 Percentage of participants — p=<.001
N/A N=151 Safety and Effectiveness of the AcuFocus Corneal Inlay ACI7000PDT in Presbyopes
Presbyopia
Primary: Uncorrected Near Visual Acuity 20/32 or Better — 73.8 percentage of subjects
Phase 3 N=333 Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia
Presbyopia
Primary: Percent of Subjects With ≥ 15 Letters of Improvement in Photopic Binocular DCNVA and With < 5 Letters of Loss in Photopic Binocular BCDVA in Nyxol-treated Subjects — 27…
N/A N=25 A Comparison of Visual Function After Bilateral Implantation of Presbyopia-Correcting Intraocular Lenses (IOLs)
Cataract
Primary: Mean Binocular Defocus VA at Month 3 — 0.78; 0.59; 0.65; 0.45 logMAR
N/A N=39 Performance of a Multifocal Contact Lens - Presbyopia Study
Presbyopia
Primary: The Total Grade of Conjunctival Hyperemia — 4.25; 3.72; 3.51; 3.42 units on a scale
N/A N=2,001 Presbyopia Screening by Community Health Worker in Bangladesh
Presbyopia
Primary: Screening Accuracy — 76.9; 75.7; 58.1; 78.3 percentage of cases
N/A N=276 Evaluation of the Performance of Investigational Contact Lenses in a Presbyopic Population
Presbyopia
Primary: Binocular Distance Visual Acuity (LogMAR) — -0.068; -0.058; -0.109; -0.107 LogMAR
N/A N=24 Extended Depth of Focus Contact Lenses for Presbyopia
Presbyopia
Primary: LogMAR Visual Acuity — -0.07 logMAR
Phase 2 N=150 Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia
Presbyopia
Primary: Percent of Subjects With ≥ 15 Letters of Improvement in Photopic Binocular DCNVA — 60.5; 30.0; 45.2; 27.3 percentage of subjects with ≥ 15 letters